Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Notebook: Clinical Trial Fatality; Affordable Medicines Debate; Physician Payment Disclosure

Executive Summary

One death and five healthy volunteers hospitalized in a Phase I study in France; EU Council looks set to debate patient access to medicines; and the two Mercks set to continue litigation in Europe and the US over use of the Merck word, straining their 60-year-old agreement. Generics/biosimilar trade group adopts physician payment disclosure policy.


Related Content

European Notebook: UK To Leave EU; Prices Attract Political Attention; Advanced Therapies Revamp
French Probe Possibility Of Manslaughter In Phase I Trial Case
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
European Notebook: Trademarks, Trade Secrets And Task Forces
European Notebook: Pricing Mistrust Needs Open Debate; Rasi Nears EMA Return; Market Turmoil Affects IPOs
European Notebook: Drug Pricing Collaborations; Biosimilar Switching; Scientific Advice
Merck Moves To Terminate 1945 DoJ Consent Decree, Open Up Deal-Making


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts